Nathan Pennell, MD, PhD | Cleveland Clinic

Dr. Nathan A. Pennell

Claim this profile

Cleveland Clinic Foundation

Expert in Lung Cancer
Expert in Non-Small Cell Lung Cancer
19 reported clinical trials
29 drugs studied

Area of expertise

1Lung Cancer
Global Leader
Nathan A. Pennell has run 17 trials for Lung Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II
2Non-Small Cell Lung Cancer
Global Leader
Nathan A. Pennell has run 15 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:
Stage IV
Stage III
RET positive

Affiliated Hospitals

Image of trial facility.
Cleveland Clinic Foundation
Image of trial facility.
Hillcrest Hospital Cancer Center

Clinical Trials Nathan A. Pennell is currently running

Image of trial facility.

Osimertinib + Bevacizumab

for Lung Cancer

This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting2 awards Phase 331 criteria
Image of trial facility.

Olomorasib

for Non-Small Cell Lung Cancer

The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to assess if olomorasib in combination with durvalumab is more effective than the durvalumab and placebo combination in part B in participants with unresectable KRAS G12C-mutant non-small cell lung cancer. The study may last up to 3 years for each participant.
Recruiting1 award Phase 38 criteria

More about Nathan A. Pennell

Clinical Trial Related3 years of experience running clinical trials · Led 19 trials as a Principal Investigator · 5 Active Clinical Trials
Treatments Nathan A. Pennell has experience with
  • Pembrolizumab
  • Docetaxel
  • Carboplatin
  • Pemetrexed Disodium
  • Gemcitabine Hydrochloride
  • Pemetrexed

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Nathan A. Pennell specialize in?
Is Nathan A. Pennell currently recruiting for clinical trials?
Are there any treatments that Nathan A. Pennell has studied deeply?
What is the best way to schedule an appointment with Nathan A. Pennell?
What is the office address of Nathan A. Pennell?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security